ArticleNature genetics2023
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response.
Open access · hybridAbstract read
In one paragraph
Article in Nature genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
9.4field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 41 citations in OpenAlex.
- Multi-omics profiling reveals homologous recombination repair hyperactivation as a therapeutic vulnerability in neuroendocrine cervical carcinoma.Signal transduction and targeted therapy · 2026Article
- [Mutation characteristics and prognosis of SF3B1-mutated myeloid neoplasms: an analysis of 183 patients].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- U2 snRNP inhibition hampers pancreatic cancer cell viability by disrupting DNA repair proficiency and mitotic checkpoint integrity.Journal of experimental & clinical cancer research : CR · 2026Article
- Tumor cell intrinsic dsRNA innate immune response triggered by PARP inhibitor is compromised in BRCA1-deficient breast cancer by repressing IRF3.Protein & cell · 2026Article
- A U1-U3 snRNA-snoRNA interaction couples SF3B1 mutation to chromatin-state rewiring and genome instability.bioRxiv : the preprint server for biology · 2026Article
- Synergistic effect of Pladienolide B and cisplatin: enhancing autophagy in hepatoma cells through the AMPK/mTOR/ULK1 pathway.Cell death discovery · 2026Article
- Spliceosomal mutation drives melanoma tumorigenesis via lineage-specific RAS activation.Science advances · 2026Article
- Cancer-associated SF3B1 mutation suppresses DNA repair by disrupting the organization of nuclear actin network.Cell death & disease · 2026Article
- Inhalation exposure to cigarette smoke promotes neointimal formation in mouse model of arterial injury.Archives of toxicology · 2026Article
- Synthetic lethality in cancer drug discovery: challenges and opportunities.Nature reviews. Drug discovery · 2026Review
- Unlocking the undruggable spliceosome: generative AI and structural dynamics in cancer therapy.Frontiers in cell and developmental biology · 2026Review
- Exploring p53 isoforms: unraveling heterogeneous p53 tumor suppressor functionality in uveal melanoma.Cell death discovery · 2025Article
- Somatic Mutation Profiling and Therapeutic Landscape of Breast Cancer in the MENA Region.Cells · 2025Article
- SF3B1-mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms.Leukemia · 2025Article
- Distinct and convergent effects ofProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Review
- Understanding and Exacerbating the Biological Response of Uveal Melanoma to Proton Beam Therapy.Cancers · 2025Review
- Advances and challenges in the treatment of myelodysplastic syndromes.Experimental hematology & oncology · 2025Review
- Pan-cancer oncogenic properties and therapeutic potential of SF3B4.Cancer gene therapy · 2025Article
- Identification of MAEA protein as a potential target for chemoresistance in osteosarcoma using bioinformatics and proteomic analysis.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 5 institutions in 3 countries.
Philip BlandThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0009-0002-1370-0359
Harry SavilleThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Patty T WaiThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Lucinda CurnowDivision of Cancer Biology, The Institute of Cancer Research, London, UK.
Gareth MuirheadThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Jadwiga NieminuszczyDivision of Cancer Biology, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0003-4672-9684
Nivedita RavindranThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Marie Beatrix JohnThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Somaieh HedayatThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Holly E BarkerThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-9350-5520
James WrightDivision of Cancer Biology, The Institute of Cancer Research, London, UK.
Lu YuDivision of Cancer Biology, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0001-8378-9112
Ioanna MavrommatiThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-5436-2619
Abigail ReadThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Barrie PeckThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-6687-8495
Mark AllenBiological Services Unit, The Institute of Cancer Research, London, UK.
Patrycja GazinskaThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Helen N PembertonThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Aditi GulatiThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Sarah NashThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Farzana NoorThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Naomi GuppyThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Ioannis RoxanisThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Guy PrattUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Ceri OldreiveInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.ORCID http://orcid.org/0000-0002-7815-8970
Tatjana StankovicInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.ORCID http://orcid.org/0000-0002-3780-274X
Samantha BarlowLiverpool Ocular Oncology Research Group, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
Helen KaliraiLiverpool Ocular Oncology Research Group, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
Sarah E CouplandLiverpool Ocular Oncology Research Group, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
Ronan BroderickDivision of Cancer Biology, The Institute of Cancer Research, London, UK.
Samar AlsafadiInserm U830, PSL University, Institut Curie, Paris, France.ORCID http://orcid.org/0000-0002-0060-1346
Alexandre HouyInserm U830, PSL University, Institut Curie, Paris, France.ORCID http://orcid.org/0000-0001-6267-2353
Marc-Henri SternInserm U830, PSL University, Institut Curie, Paris, France.ORCID http://orcid.org/0000-0002-8100-2272
Stephen PettitThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0003-3313-3857
Jyoti S ChoudharyDivision of Cancer Biology, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0003-0881-5477
Syed HaiderThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0001-6685-5480
Wojciech NiedzwiedzDivision of Cancer Biology, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-8518-6304
Christopher J LordThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-3226-0515
Rachael NatrajanThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. rachael.natrajan@icr.ac.uk.ORCID http://orcid.org/0000-0002-9987-2946
Institute of Cancer Research · GBInserm · FRUniversity of Liverpool · GBUniversity of Birmingham · GBUniversity Hospitals Birmingham NHS Foundation Trust · GB
Funding
Cancer Research UK A24881Cancer Research UK C20807/A28640Cancer Research UK RCCCEA-NOV22/100006Medical Research Council MC_PC_16047Wellcome Trust
Abstract
SF3B1 hotspot mutations are associated with a poor prognosis in several tumor types and lead to global disruption of canonical splicing. Through synthetic lethal drug screens, we identify that SF3B1 mutant (SF3B1
Indexed as
NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinCell Line, TumorHumansMutationPhosphoproteinsRNA Splicing FactorsTranscription FactorsBRCA1 ProteinPhosphoproteinsPoly(ADP-ribose) Polymerase InhibitorsRNA Splicing FactorsSF3B1 protein, humanTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.